



Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis

Thibault Fiolet, Anthony Guihur, Mathieu Edouard Rebeaud, Matthieu Mulot, Nathan Peiffer-Smadja, Yahya Mahamat-Saleh

► To cite this version:

Thibault Fiolet, Anthony Guihur, Mathieu Edouard Rebeaud, Matthieu Mulot, Nathan Peiffer-Smadja, et al.. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. *Clinical Microbiology and Infection*, 2021, 27 (1), pp.19-27. 10.1016/j.cmi.2020.08.022 . hal-03127508

HAL Id: hal-03127508

<https://hal.science/hal-03127508>

Submitted on 2 Jan 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

CLM-20-18519.R1

Title: Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis

Thibault Fiolet^{1, 2*}, Anthony Guihur³, Mathieu Rebeaud³, Matthieu Mulot⁴, Nathan Peiffer-Smadja^{5, 6, 7},
Yahya Mahamat-Saleh^{1, 2}

¹CESP (Center for Research in Epidemiology and Population Health), Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris Saclay, 94 805, Villejuif, France

²Gustave Roussy, F-94805, Villejuif, France

³Department of Plant Molecular Biology, Faculty of Biology and Medicine, University of Lausanne, Switzerland

⁴Laboratory of Soil Biodiversity, Faculty of Science, University of Neuchâtel, Switzerland.

⁵Université de Paris, IAME, INSERM, F-75018 Paris, France.

⁶National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.

⁷Infectious and Tropical Diseases Department, Bichat-Claude Bernard Hospital, AP-HP, Paris, 75018, France.

Corresponding author:

*Thibault Fiolet, MSc, PhD candidate in Epidemiology

Center for Research in Epidemiology and Population Health

Inserm U1018 “Health across Generations” Team and Paris-Sud 11 University/Paris-Saclay University

114 rue Edouard Vaillant

94805 Villejuif Cedex

Tel: (+33) 1-42-11-56-45 / Mobile: (+33) 6-79-50-91-19

E-mail: Thibault.fiolet@gustaveroussy.fr

Twitter: @T_Fiolet

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

Word count of Abstract: 313

Word count (without Abstract, Materials, References, Figures and tables): 3 451

Number of figures: 3

Number of tables: 1

Supplemental material:

Supplementary Figures: 10

Supplementary Tables: 6

Supplementary Texts: 2

Supplementary File: 1 Excel file

57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84

Abstract

Background

Hydroxychloroquine or chloroquine with or without azithromycin have been widely promoted to treat COVID-19 following early *in vitro* antiviral effects against SARS-CoV-2

Objective

The aim of this systematic review and meta-analysis was to assess whether chloroquine or hydroxychloroquine with or without azithromycin decreased COVID-19 mortality compared to the standard of care

Data sources

Pubmed, Web of Science, Embase Cochrane Library, Google Scholar and MedRxiv were searched until 25 July 2020

Study eligibility criteria

We included published and unpublished studies comparing the mortality rate between patients treated with chloroquine or hydroxychloroquine with or without azithromycin and patients managed with standard of care

Participants

Patients ≥18 years old with confirmed COVID-19

Interventions

Chloroquine or hydroxychloroquine with or without azithromycin

Methods

Effect sizes were pooled using a random-effects model. Multiple subgroup analyses were conducted to assess the drug safety

Results

The initial search yielded 839 articles, of which 29 articles met our inclusion criteria. All studies except one were conducted on hospitalized patients and evaluated the effects of hydroxychloroquine with or without azithromycin. Among the 29 articles, 3 were randomized controlled trials (RCT), one was a non-randomized trial and 25 were observational studies, including 10 with a critical risk of bias

and 15 with a serious or moderate risk of bias. After excluding studies with critical risk of bias, the meta-analysis included 11,932 participants for the hydroxychloroquine group, 8,081 for the hydroxychloroquine with azithromycin group and 12,930 for the control group. Hydroxychloroquine was not significantly associated with mortality: pooled Relative Risk $RR=0.83$ (95% CI: 0.65-1.06, $n=17$ studies) for all studies and $RR=1.09$ (95% CI: 0.97-1.24, $n=3$ studies) for RCTs. Hydroxychloroquine with azithromycin was associated with an increased mortality: $RR=1.27$ (95% CI: 1.04-1.54, $n=7$ studies). We found similar results with a Bayesian meta-analysis.

Conclusion

Hydroxychloroquine alone was not associated with reduced mortality in hospitalized COVID-19 patients but the combination of hydroxychloroquine and azithromycin significantly increased mortality.

Abbreviations: HCQ: Hydroxychloroquine; AZI: Azithromycin; CI: Confidence Interval; RR: Relative Risk; HR: Hazard Ratio, OR: Odds Ratio; RCT: Randomized Controlled Trial; US FDA: US Food and Drug Administration; EMA: European Medicine Agency

Introduction

On December 31, 2019, the World Health Organization (WHO) identified an unknown pneumonia caused by a new coronavirus, SARS-CoV-2, in Wuhan, China. By July 30, 2020, WHO confirmed more than 17 million cases and 667,935 deaths [1]. Chloroquine (CQ) and its derivative hydroxychloroquine (HCQ) were rapidly identified as potential drug candidates since CQ had an antiviral activity against Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) *in vitro* [2]. An *in vitro* antiviral activity of the aminoquinolines HCQ and CQ was confirmed against SARS-CoV-2 and a study reported a synergistic effect of the HCQ with azithromycin (AZI) against SARS-CoV-2 [3]. These drugs appeared as potential low-cost treatments for COVID-19 patients [4–7] and received wide and speculative coverage by the international press and the United States President [8].

Subsequently, HCQ and AZI were tested in a study where macaques were infected by SARS-CoV-2 and received either a high dose of HCQ (90 mg/kg on day 1 then 45 mg/kg) or a low HCQ dose (30 mg/kg on day 1 then 15 mg/kg) [9]. HCQ with or without AZI did not improve the time to viral clearance regardless of the stage of disease: prophylaxis, early treatment or late treatment.

Among the on-going trials, CQ or HCQ are among the most studied drugs [10,11]. Until today, most of the published studies on HCQ with a comparative group (standard care) were observational and non-randomized with inconsistent results [12–18]. Given the magnitude of the COVID-19 pandemic and the need for effective therapeutics, timely meta-analyses can play an important role in assessing the impacts of CQ and HCQ comparatively with standard of care on reliable clinical outcomes such as mortality. Previous meta-analyses on COVID-19 included a limited number of studies and used unadjusted risk ratios [19–21].

The aim of this systematic review and meta-analysis was to assess whether chloroquine or hydroxychloroquine with or without azithromycin decreased the mortality of COVID-19 compared to standard of care.

Methods

The research question was: in patients with confirmed COVID-19, is the addition of hydroxychloroquine or chloroquine with or without azithromycin to the standard of care, effective in improving survival?

PICO question:

Population: patients with confirmed COVID-19

Intervention: HCQ or CQ, with or without AZI

Comparison: a standard of care

Outcomes: the survival rate of COVID-19 patients

Data sources, search strategy

A search was performed using PubMed, Web of Science, Embase and Cochrane Review up to July 25, 2020 with the following string search: (COVID-19 OR SARS-CoV-2) AND (MORTALITY OR DEATH) AND (HYDROXYCHLOROQUINE OR HCQ) (Supplementary text S1). Given that the number of articles about HCQ and COVID-19 is rapidly growing, we also manually searched for additional references on the MedRxiv preprint server and on Google Scholar with the same terms. An additional search on PubMed, Web of Science and Cochrane Review was conducted for chloroquine with the search terms described in Supplementary materials S1: (COVID-19 OR SARS-CoV-2) AND (MORTALITY OR DEATH) AND (CHLOROQUINE OR CQ). This meta-analysis was conducted following PRISMA statements in Supplementary text S2. This study has been recorded on the international database of prospectively registered systematic reviews, PROSPERO (Registration number: CRD42020190801).

Study selection:

Study selection was conducted by two investigators (TF and YM) who screened the titles and the abstracts. Discrepancies were resolved by a third investigator (AG). Inclusion criteria were 1) reports containing original data with available risk estimates (Hazard Ratios, Odds Ratios, Relative Risk and/or with data on the number of deaths in HCQ/CQ and control groups; 2) any publication dates; 3) comparative studies with a control group without HCQ nor CQ; and 4) COVID-19 confirmed cases by

RT-PCR. Studies reporting no deaths, reviews and meta-analyses, commentaries, editorials and *in vitro* and *in vivo* animal studies were excluded.

Data extraction

Two investigators (TF and YM) extracted the following data for each study: study design, publication date, journal, location, number of participants and deaths (in treatment and control groups), HCQ or CQ doses when available, effect size (Hazard Ratio, Odds Ratio or Relative Risk) and 95% confidence intervals for reported risk estimates. The estimates from the model, adjusted for the maximum number of covariates were used to control potential confounders, according to Cochrane Methodology [22]. For each study, risk factors associated with higher mortality were taken into account through the reported adjusted effect sizes.

When studies did not report an effect size for mortality risk [17,23,24], we used the number of deaths per group to calculate an unadjusted relative risk using *metabin* function in *meta* package in R Software [25].

For all the other studies, reported adjusted OR, RR or HR were used.

Individual risk of bias

The quality of each study was assessed with ROBINS-I tool following Cochrane guidelines for non-randomized studies and with Rob2 for randomized studies [26,27].

Outcome

The outcome was the mortality of COVID-19 patients.

Statistical analysis

Effect of CQ/HCQ alone and HCQ + AZI

A primary meta-analysis was performed to compare the survival rate (or mortality) between patients treated with CQ or HCQ and standard of care. Then, the relationship between HCQ associated with

AZI and mortality was assessed. HRs, ORs and RRs were treated as equivalent measures of mortality risk. Pooled RRs were determined by using a random effect model with inverse variance weighting (DerSimonian-Laird method) [28]. Significance was checked using a Z-test, where $p < 0.05$ is considered as significant. The absolute risk difference was calculated from the UK baseline hospital mortality risk of 26% (according to ISARIC WHO CCP-UK cohort based on 20,133 patients) using the formula $RD = BR \times (RR - 1)$ [29].

Heterogeneity was assessed by the Cochrane Q test and I^2 test [30]. $30\% < I^2 < 60\%$ was interpreted as moderate heterogeneity and $I^2 > 60$ as substantial heterogeneity. A funnel plot was constructed to assess the publication bias. Begg's and Egger's tests were conducted to assess the publication bias [31,32]. RR or HR were used to assessed mortality risk within a 95% confidence interval. In the main analysis, studies with critical bias were excluded. A sensitivity analysis including these studies, was conducted. A Bayesian meta-analysis was performed to test the robustness of our results, allowing incorporation of full uncertainty in all parameters [33]. The traditional random-effect model has fixed parameters for the distribution of the true treatment effect RR with an unknown mean θ , within-study variance σ^2 and between study variance τ^2 . The Bayesian random-effect model assumes these parameters are random with a probability distribution. Two prior distributions were tested $\mu \sim \text{Normal}(1, 100)$ with a large variance and $\tau \sim \text{Half-Cauchy}(0, 0.5)$ and a second scenario with $\mu \sim \text{Normal}(1, 1)$ and $\tau \sim \text{Half-Cauchy}(0, 0.5)$. The Bayesian analysis was conducted with the R package "brms" [34].

Subgroup analysis

Subgroup analyses were further conducted according to the quality assessment to explore the source of heterogeneity among observational studies. We performed stratified analyses by type of article (peer-reviewed vs unpublished), use of an adjustment on confounding factors (studies with $RR_{\text{unadjusted}}$ vs RR_{adjusted}), mean daily dose of HCQ or CQ (continuous), median population age across the studies, level of bias risk identified with ROBIN-I (moderate/serious/critical) [26] and when we excluded studies with cancer and dialysis patients. Mean daily dose of HCQ or CQ was the daily average

between the loading dose and the maintenance doses. Additionally, influence analysis was conducted by omitting each study to find potential outliers [34]. Influence analysis is used to detect studies which influence the overall estimate of a meta-analysis the most, omitting one study at a time (leave-one-out method).

A two-sided p-value <0.05 was considered statistically significant. All analysis were conducted using R version 3.6.1 with *meta* package and *robvis* package [35].

Results

Literature Search

A flow chart is presented in Figure 1. After searching Pubmed, Cochrane Review and Web of Science, 839 articles were identified. After screening the title and the abstract, only 21 articles about hydroxychloroquine and COVID-19 were included for further consideration. We excluded 564 articles that did not meet the inclusion criteria. We did not find any non-English articles meeting our inclusion criteria. Two duplicate studies on the same cohort were excluded [12,36]. Two Chinese randomised controlled trials on hydroxychloroquine reported zero deaths in both treatment and control groups [37,38] and thus their results were not included in our meta-analysis. Ten articles from Medrxiv/Google Scholar were added. Thus, 29 articles were included, of which 25 were observational studies, one was an interventional non-randomized study and three were randomized controlled trials (RCT). These studies included 27 articles for HCQ [14–19,23,24,36,39–56] and 12 articles for HCQ+AZI [18,36,41,42,47,48,50,51,57–60]. For CQ, after searching Pubmed, Cochrane Review, Embase and Web of Science, 449 articles were identified. After screening the title and the abstract, only 1 Brazilian RCT and 3 observational studies studied chloroquine and COVID-19. However, among these studies, Gabriela Silva Borba et al. and Saleh et al. studies did not have a standard of care comparative group [61,62]. Khamis et al. did not report death data related to chloroquine and Huang et al. did not report any death [63,64]. Consequently, no study on chloroquine met our inclusion criteria.

Study characteristics

This meta-analysis included 15,190 patients in the HCQ group, 8081 patients in the HCQ with AZI and 14,060 patients in the standard of care group with 3,152 deaths, 1,063 deaths and 2,857 deaths, respectively. Individual studies are described in Tables S1 and S2. All included studies except one (Skipper et al.) were carried out on hospitalized patients [39]. Mean ($\pm$ SD) age of participants was 62.1 ± 8.5 years. Ten studies were conducted in the USA [15,18,23,41,42,49,50,53,56,58], 4 in Spain [16,17,44,57], 7 in France [13,24,46,48,54,59,60], one in the UK [40], two in Italy [43,65], one in China [14], one in Brazil [51] and three in several other countries (USA, Canada, Italy and Spain)[39,47,52]. Twenty-two articles were published [13–15,17,18,24,39,41,43,44,46,49–54,56,57,59,60,65], and 6 articles were preprints [16,23,40,42,48,58]. Mean daily dose of HCQ ranged from 333 mg/j to 945 mg/j. Few studies precisely described concomitant use of corticosteroids (Table S3) [15–17,44,48,50–52,65]. Only the RECOVERY trial precisely reported the use of dexamethasone (8% vs 9% in both arms) [40].

Study quality

Risk of bias was assessed with ROBINS-I for non-randomised studies (n=26) and Rob2 for RCT (n=3) (Figures S1-S2). Three RCT had some concerns [39,40,51] and one interventional non-randomized study had critical risk of bias [24]. Among the observational studies, fifteen articles had a moderate or serious risk of bias [13–18,41,42,44,46–48,56,58] and ten studies had a critical risk of bias [23,43,49,50,52–54,59,60,65]. Eleven observational studies did not report adjusted effect sizes to control confusion and selection bias [23,24,43,44,49,53,54,57,59,60,65]. Quality of studies was lowered by the lack of information about the assignment of treatment, the time between start of follow-up and start of intervention), some unbalanced co-intervention with other antiviral and antibiotic drugs and imbalance between groups for confounders such as comorbidities and age.

Hydroxychloroquine and mortality

After excluding studies with critical bias, the pooled RR for COVID-19 mortality was 0.83 (95%CI: 0.65-1.06, n=17 studies) indicating no significant association between HCQ and COVID-19 mortality (Figure 2). Under the hypothesis of having a baseline mortality risk of 26% (based on ISARIC WHO

CCP-UK cohort [29]), these pooled relative risk values would correspond to a non-significant risk difference of -4.4% [29] (Table 1). There was a significant subgroup difference between RCT and non-randomized studies ($P_{\text{heterogeneity between}} = 0.03$) with respectively $RR_{\text{RCT}}=1.09$ (95%CI: 0.97-1.24) and $RR_{\text{non-randomized}}= 0.79$ (95%CI: 0.60-1.04) (Figure 2). Among observational studies with a moderate risk of bias, we found no association between HCQ and mortality $RR_{\text{moderate bias}}=1.03$ (95%CI: 0.91-1.17, $P=0\%$, $n=7$ studies) with no subgroup heterogeneity (Table S4, Figure S3). Results remained nonsignificant with influence analysis (Figure S4). The Bayesian meta-analysis led to similar results with a pooled RR for mortality of 0.93 (95%CI: 0.72-1.14, $n=17$ studies) (Table S5, Figure S5). In sensitivity analysis, after inclusion of studies with critical risk of bias, the global RR was marginally not significant 0.80 (95%CI: 0.65-1.00) (Table S6).

Outcome: all-cause mortality	Number of studies	Pooled Relative Risk	Risk difference
Hydroxychloroquine alone			
All studies	17	0.83 [0.65-1.06]	-4.4% [-9% ; +1.5%]
Non-randomized studies	14	0.79 [0.60-1.04]	-5.5% [-10% ; +1%]
Randomized studies	3	1.09 [0.97-1.24]	+2.3% [-0.8% ; +6.2%]
Hydroxychloroquine with azithromycin			
All studies	7	1.27 [1.04-1.54]	+7% [+1% ; +14%]
Non-randomized studies	6	1.29 [1.06-1.58]	+7.5% [+1.6% ; +15%]
Randomized studies	1	0.64 [0.18-2.24]	-9% [-21% ; +32%]

Table 1: Relative risk and risk difference for mortality associated with hydroxychloroquine with or without azithromycin, assuming a UK mortality rate in hospital of 26% according to ISARIC WHO CCP-UK cohort.

There was a significant higher heterogeneity among non-randomised studies as compared to RCT ($I^2=84\%$, $P_{\text{heterogeneity within}} < 0.01$). In fact, heterogeneity was null for RCT. Egger's test ($p=0.68$) and Begg's test ($P=0.13$) were not significant for asymmetry of the funnel plot indicating that there was no major publication bias for non-randomized studies (Figure S6).

Hydroxychloroquine with azithromycin and mortality

After exclusion of studies with critical bias, the pooled RR for COVID-19 mortality was 1.27 (95%CI: 1.04-1.54, n=7) indicating an increased mortality linked to the use of hydroxychloroquine with azithromycin. With a baseline hospital mortality of 26%, we identified a significant absolute risk difference of +7%. We found an increased risk of mortality in patients treated with hydroxychloroquine and azithromycin compared to standard of care (RR: 1.29 (95%CI: 1.06-1.58, n=6)) among non-randomized studies but this relationship was not found in the single Brazilian RCT, with no heterogeneity observed across the study design ($P_{\text{heterogeneity between}} = 0.28$) (Figure 3). There was a low heterogeneity across the included studies ($I^2 = 38\%$, $p=0.14$). Egger's test ($p= 0.70$) and Begg's test ($p=0.65$) were not significant but the asymmetry in the funnel plot indicates that a publication bias could be present (Figure S7). However, the number of included studies was small. Subgroup analyses are described in supplementary material (Table S4, Figure S8). The Bayesian meta-analysis led to similar results with a pooled RR for mortality of 1.32 (95%CI: 0.97-1.68, n=7 studies) (Table S5, Figure S9). The increase in mortality was also significant with influence analysis (Figure S10).

Discussion

This meta-analysis summarized the results of 25 observational studies, three randomised controlled trials and one interventional non-randomised study on the effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients (Table 1). Despite our inclusion criteria that did not specify the stage of the disease, all the studies were conducted with hospitalized patients except the RCT by Skipper et al. RCT [39]. Our results show that while hydroxychloroquine alone was not associated with reduced mortality in COVID-19 patients, the combination of hydroxychloroquine and azithromycin significantly increased mortality. We found similar results with a Bayesian analysis.

Our meta-analysis reported a high heterogeneity for hydroxychloroquine alone, but this heterogeneity was lowered among RCT, studies with moderate risk of bias and for the association of HCQ+AZI. The various quality of studies (not reporting HCQ dose, the lack of adjustment in reported estimates) may explain one part of the heterogeneity observed according to our subgroup analysis (Table S4).

325

326 A previous systematic review only included 8 studies on all-cause mortality in COVID-19 patients
327 [13–16,23,38,41,66] and concluded that the level of evidence for hydroxychloroquine effect was very
328 weak[67]. A preprint meta-analysis, using routinely collected records from clinical practice in
329 Germany, Spain, the UK, Japan, and the USA, compared the use of HCQ with sulfasalazine [68]. This
330 study observed an increased risk of 30-day cardiovascular mortality (HR=2.19 [1.22-3.94]), although
331 the study lacked a standard of care comparative group. Some previous meta-analyses were also
332 conducted on hydroxychloroquine and various health endpoints including mortality. However these
333 studies did not report all the published and unpublished literature, including a very limited number of
334 studies: from 3 articles[19,20] to 6 articles[21]. These previous meta-analyses did not perform
335 subgroup and sensitivity analysis to test the effect of pooling RCT and observational study, nor did
336 they study the source of heterogeneity. They used unadjusted risk ratio (calculated with the number of
337 events in each group) whereas in our meta-analysis, we used adjusted relative risk [69] and we ran
338 sensitivity analysis on the adjustment of effect size. Statistical adjustments for key prognostic
339 variables limit confusion bias, especially in observational studies which are not randomised. This
340 meta-analysis confirmed the partial preliminary results of these other meta-analyses about the absence
341 of effect for HCQ on survival and found an increased mortality with the use of the combination of
342 HCQ with AZI in COVID-19 patients. These results confirm the preliminary findings of several
343 observational studies which have shown that the combination of hydroxychloroquine and
344 azithromycin might increase the risk of acute, life-threatening cardiovascular events [70]. A first study
345 found that, among patients treated with this combination, 6 out of 18 (33%) developed a significant
346 increase in the QTc interval.[71] Another work found that in 84 patients treated with HCQ + AZI, 9
347 had a severe prolongation of QTc [72]. The combination of HCQ + AZI was associated with a greater
348 variation in the QTc interval compared to hydroxychloroquine alone in a study with 90 patients [73].
349 In a study conducted in New York on 1438 patients cardiac arrest was significantly more likely in
350 patients receiving hydroxychloroquine with azithromycin compared to patients receiving neither of the
351 two drugs (adjusted OR, 2.13 [95% CI, 1.12-4.05]) [18]. Finally, a study conducted on the WHO

database bringing together more than 167,000 patients found an increased risk of potentially fatal acute cardiac events in patients treated with azithromycin alone or with hydroxychloroquine alone [74]. The combination of the two drugs posed an even greater risk of life-threatening acute cardiac effects [18,73,74].

Several national health organisations (US FDA Food and Drug Administration[75], French Agency for the Safety of Health Products ANSM [76], European Medicine Agency EMA [77]) raised concerns about using unapproved drugs for COVID-19. ANSM and US FDA removed the authorization for the use of HCQ outside of clinical trials. The Indian Council of Medical Research took the opposite position and recommended chemoprophylaxis with hydroxychloroquine for asymptomatic cases [78]. Finally, in the comparative peer-reviewed studies, a clear conclusion on hydroxychloroquine is not possible due to the small sample size, the lack of well-performed randomised controlled trials (mainly non-randomised and retrospective studies) and inconsistent results. Many preprints without a comparative group and without randomization added to confusion surrounding this highly politicised topic[79]. There is a gap between the speed of clinical research and the expectation of a clear solution to treat COVID-19 patients. Indeed, producing robust clinical trials is necessarily time-consuming. In a press communication, on 20 June 2020, US National Institutes of Health (NIH) stopped the clinical trial of hydroxychloroquine since this drug was very unlikely to be efficient to treat COVID-19 patients [80]. Based on SOLIDARITY trial results, WHO previously undertook the same decision [81].

A Bayesian meta-analysis confirmed our findings from classical random-effect meta-analysis. We included several unpublished papers to minimize the publication bias. Our subgroup analysis by published studies (vs unpublished studies) found that the inclusion of preprints did not change the results. Exclusion of grey literature (unpublished studies, with limited distribution) could lead to an exaggeration of the intervention effect by 15% [82]. There is limited evidence to identify whether grey studies have a poorer methodological quality than published studies[83].

379

380 A major limitation is the inclusion of patients at different levels of COVID-19 severity. However, we
381 could not conduct subgroup analysis for severity since most of studies reports do not use the same
382 definition of severity and do not report the same biological and clinical outcomes. We also noted a
383 high level of heterogeneity in the administration of HCQ (dosing, timing between hospital
384 administration and intervention, duration...). In some studies, these data were not reported at all.
385 Another limitation comes from the studies which did not report adjusted effect size when mortality
386 was not the primary endpoint, leading to a high risk of confounding bias. As is usually done, this
387 meta-analysis was based on aggregated data, without access to original patient data. Most of the
388 included studies were observational which are not adapted to identify a causal association. Indeed,
389 some of the included studies had very low quality of evidence (missing data, small sample size,
390 confusion bias, bias in classification of intervention and selection bias), although our supplementary
391 analyses and the exclusion of these articles did not change the results. Finally, this meta-analysis did
392 not include results from the European DisCoVeRy trial and the WHO Solidarity trial that are not yet
393 published or communicated [81].

394

395 In conclusion, this meta-analysis clearly shows that hydroxychloroquine alone is not effective for the
396 treatment of COVID-19 patients and that the combination of hydroxychloroquine and azithromycin
397 increases the risk of mortality. These data support current clinical recommendations such as those of
398 the NIH [84] which do not recommend the use of HCQ alone or in combination with azithromycin for
399 COVID-19 patients. There is already a great number of studies that have evaluated HCQ alone or in
400 combination [10] and it seems unlikely at this stage that any efficacy will ever emerge. Our results
401 suggest that there is no need for further studies evaluating these molecules, and the European
402 DisCoveRy clinical trial or the WHO international Solidarity clinical trial have already discontinued
403 treatment arms using hydroxychloroquine [81,85].

404

405 **Conflict of interests:** All authors declare: no support from any organisation for the submitted work
406 other than that described above; no financial relationships with any organisations that might have an

interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Funding: There was no specific funding for this meta-analysis.

Acknowledgments: The authors would like to thank Dominique Meroux for proofreading the manuscript. We also thank Drifa Belhadi for her helpful comments on the manuscript.

Contribution: TF designed the research. TF, MR, AG, MM, NPS and YMS conducted the research. TF did the statistical analysis. TF wrote the first draft of the paper. MR, AG, MM, NPS and YMS contributed to the writing of the paper. All authors contributed to the data interpretation, revised each draft for important intellectual content, and read and approved the final manuscript.

References

- [1] World Health Organization (WHO). Coronavirus disease (COVID-19). Situation Report - 153. n.d.
- [2] Dyal J, Gross R, Kindrachuk J, Johnson RF, Olinger GG, Hensley LE, et al. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. *Drugs* 2017;77:1935–66. <https://doi.org/10.1007/s40265-017-0830-1>.
- [3] Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. *Microb Pathog* 2020;145:104228. <https://doi.org/10.1016/j.micpath.2020.104228>.
- [4] Hill A, Wang J, Levi J, Heath K, Fortunak J. Minimum costs to manufacture new treatments for COVID-19. *J Virus Erad* 2020;6:61–9.
- [5] Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis* n.d. <https://doi.org/10.1093/cid/ciaa237>.
- [6] Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discovery* 2020;6:1–4. <https://doi.org/10.1038/s41421-020-0156-0>.
- [7] Maisonnasse. Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non-human primates 2020. <https://doi.org/10.21203/rs.3.rs-27223/v1>.
- [8] DeJong C, Wachter RM. The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19—First, Do No Harm. *JAMA Intern Med* 2020. <https://doi.org/10.1001/jamainternmed.2020.1853>.
- [9] Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, Marlin R, et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. *Nature* 2020:1–8. <https://doi.org/10.1038/s41586-020-2558-4>.

- [10] Fragkou PC, Belhadi D, Peiffer-Smadja N, Moschopoulos CD, Lescure F-X, Janocha H, et al. Review of trials currently testing treatment and prevention of COVID-19. *Clinical Microbiology and Infection* 2020;26:988–98. <https://doi.org/10.1016/j.cmi.2020.05.019>.
- [11] Peiffer-Smadja N, Lescure F-X, Sallard E, Ravaud P, Vegreville B, Zeitoun J-D. Anticovid, a comprehensive open-access real-time platform of registered clinical studies for COVID-19. *J Antimicrob Chemother* n.d. <https://doi.org/10.1093/jac/dkaa223>.
- [12] Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet* 2020. [https://doi.org/10.1016/S0140-6736\(20\)31187-9](https://doi.org/10.1016/S0140-6736(20)31187-9).
- [13] Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. *BMJ* 2020;369. <https://doi.org/10.1136/bmj.m1844>.
- [14] Yu B, Li C, Chen P, Zhou N, Wang L, Li J, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with. *Sci China Life Sci* 2020:1–7. <https://doi.org/10.1007/s11427-020-1732-2>.
- [15] Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 2020. <https://doi.org/10.1056/NEJMoa2012410>.
- [16] Membrillo FJ, Ramírez-Olivencia G, Estébanez M, Dios B de, Herrero MD, Mata T, et al. Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study 2020. <https://doi.org/10.20944/preprints202005.0057.v2>.
- [17] Ayerbe L, Risco C, Ayis S. The association between treatment with heparin and survival in patients with Covid-19. *J Thromb Thrombolysis* 2020:1–4. <https://doi.org/10.1007/s11239-020-02162-z>.
- [18] Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA* 2020. <https://doi.org/10.1001/jama.2020.8630>.
- [19] Singh AK, Singh A, Singh R, Misra A. “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”. *Diabetes Metab Syndr* 2020;14:589–96. <https://doi.org/10.1016/j.dsx.2020.05.017>.
- [20] Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. *J Med Virol* 2020;92:776–85. <https://doi.org/10.1002/jmv.25898>.
- [21] Patel TK, Barvaliya M, Kevadiya BD, Patel PB, Bhalla HL. Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review. *J Neuroimmune Pharmacol* 2020. <https://doi.org/10.1007/s11481-020-09930-x>.
- [22] Cochrane Training. Cochrane Handbook for Systematic Reviews of Interventions. Part 3: Special topics. 13.6.2.2 Combining studies (version 6) 2019. https://handbook-5-1.cochrane.org/chapter_13/13_6_2_2_combining_studies.htm (accessed July 28, 2020).
- [23] Barbosa Joshua, Kaitis Daniel, Freedman Ryan, Le Kim, Lin Xihui. Clinical Outcomes of Hydroxychloroquine in Hospitalized Patients with COVID-19: a Quasi-Randomized Comparative Study. *Dropbox* 2020. https://www.dropbox.com/s/urzapkyij542qx5/NEJM_Clinical%20Outcomes%20of%20Hydroxychloroquine%20in%20Patients%20with%20COVID19.pdf.pdf.pdf.pdf.pdf.pdf.pdf.pdf?dl=0 (accessed June 8, 2020).
- [24] Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International Journal of Antimicrobial Agents* 2020:105949. <https://doi.org/10.1016/j.ijantimicag.2020.105949>.
- [25] Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Health* 2019;22:153–60. <https://doi.org/10.1136/ebmental-2019-300117>.

- [26] Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016;355. <https://doi.org/10.1136/bmj.i4919>.
- [27] Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366. <https://doi.org/10.1136/bmj.l4898>.
- [28] DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clinical Trials* 1986;7:177–88. [https://doi.org/10.1016/0197-2456\(86\)90046-2](https://doi.org/10.1016/0197-2456(86)90046-2).
- [29] Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020;369. <https://doi.org/10.1136/bmj.m1985>.
- [30] Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539–58. <https://doi.org/10.1002/sim.1186>.
- [31] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50:1088–101.
- [32] Al-Bari MdAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. *Pharmacol Res Perspect* 2017;5:e00293. <https://doi.org/10.1002/prp2.293>.
- [33] Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. *J R Stat Soc Ser A Stat Soc* 2009;172:137–59. <https://doi.org/10.1111/j.1467-985X.2008.00552.x>.
- [34] Viechtbauer W, Cheung MW-L. Outlier and influence diagnostics for meta-analysis. *Res Synth Method* 2010;1:112–25. <https://doi.org/10.1002/jrsm.11>.
- [35] McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. *Res Synth Methods* 2020. <https://doi.org/10.1002/jrsm.1411>.
- [36] Wang A-L, Zhong X, Hurd Y. Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System. *Infectious Diseases (except HIV/AIDS)*; 2020. <https://doi.org/10.1101/2020.06.11.20128926>.
- [37] Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ* 2020;369. <https://doi.org/10.1136/bmj.m1849>.
- [38] CHEN Jun LD, CHEN Jun LD. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. *J Zhejiang Univ (Med Sci)* 2020;49:215–9. <https://doi.org/10.3785/j.issn.1008-9292.2020.03.03>.
- [39] Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. *Annals of Internal Medicine* 2020. <https://doi.org/10.7326/M20-4207>.
- [40] Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. *MedRxiv* 2020:2020.07.15.20151852. <https://doi.org/10.1101/2020.07.15.20151852>.
- [41] Magagnoli J, Narendran S, Pereira F, Cummings TH, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. *Med* 2020;0. <https://doi.org/10.1016/j.medj.2020.06.001>.
- [42] Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclair BA, et al. Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study. *Infectious Diseases (except HIV/AIDS)*; 2020. <https://doi.org/10.1101/2020.05.21.20109207>.
- [43] Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. *Kidney Int* 2020. <https://doi.org/10.1016/j.kint.2020.04.030>.

- [44] Sánchez-Álvarez JE, Fontán MP, Martín CJ, Pelicano MB, Reina CJC, Prieto ÁMS, et al. Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN). *Nefrología (English Edition)* 2020. <https://doi.org/10.1016/j.nefro.2020.04.002>.
- [45] Wilkinson E. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials. *BMJ* 2020;369. <https://doi.org/10.1136/bmj.m1626>.
- [46] Paccoud O, Tubach F, Baptiste A, Bleibtreu A, Hajage D, Monsel G, et al. Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital. *Clin Infect Dis* n.d. <https://doi.org/10.1093/cid/ciaa791>.
- [47] Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu C-Y, et al. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study. *Cancer Discov* 2020. <https://doi.org/10.1158/2159-8290.CD-20-0941>.
- [48] Sbidian E, Josse J, Lemaitre G, Mayer I, Bernaux M, Gramfort A, et al. Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France. *MedRxiv* 2020:2020.06.16.20132597. <https://doi.org/10.1101/2020.06.16.20132597>.
- [49] Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, et al. COVID-19 in patients with lung cancer. *Ann Oncol* 2020. <https://doi.org/10.1016/j.annonc.2020.06.007>.
- [50] Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huising K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. *International Journal of Infectious Diseases* 2020;97:396–403. <https://doi.org/10.1016/j.ijid.2020.06.099>.
- [51] Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *New England Journal of Medicine* 2020;0:null. <https://doi.org/10.1056/NEJMoa2019014>.
- [52] Cravedi P, Suraj SM, Azzi Y, Haverly M, Farouk S, Pérez-Sáez MJ, et al. COVID-19 and Kidney Transplantation: Results from the TANGO International Transplant Consortium. *American Journal of Transplantation* n.d.;n/a. <https://doi.org/10.1111/ajt.16185>.
- [53] Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. *JAMA Intern Med* 2020. <https://doi.org/10.1001/jamainternmed.2020.3596>.
- [54] Lecronier M, Beurton A, Burrel S, Haudebourg L, Deleris R, Le Marec J, et al. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. *Crit Care* 2020;24:418. <https://doi.org/10.1186/s13054-020-03117-9>.
- [55] Fontana F, Giaroni F, Frisina M, Alfano G, Mori G, Lucchi L, et al. SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience. *Clin Kidney J* 2020;13:334–9. <https://doi.org/10.1093/ckj/sfaa084>.
- [56] Mikami T, Miyashita H, Yamada T, Harrington M, Steinberg D, Dunn A, et al. Risk Factors for Mortality in Patients with COVID-19 in New York City. *J Gen Intern Med* 2020:1–10. <https://doi.org/10.1007/s11606-020-05983-z>.
- [57] Rogado J, Obispo B, Pangua C, Serrano-Montero G, Martín Marino A, Pérez-Pérez M, et al. Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid. *Clin Transl Oncol* 2020:1–5. <https://doi.org/10.1007/s12094-020-02381-z>.
- [58] Singh S, Khan A, Chowdhry M, Chatterjee A. Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a Federated Electronic Medical Record Network. *Infectious Diseases (except HIV/AIDS)*; 2020. <https://doi.org/10.1101/2020.05.12.20099028>.
- [59] Lagier J-C, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in

- Marseille, France: A retrospective analysis. *Travel Medicine and Infectious Disease* 2020;101791. <https://doi.org/10.1016/j.tmaid.2020.101791>.
- [60] Bousquet G, Falgarone G, Deutsch D, Derolez S, Lopez-Sublet M, Goudot F-X, et al. ADL-dependency, D-Dimers, LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with Covid-19. *Aging (Albany NY)* 2020;12:11306–13. <https://doi.org/10.18632/aging.103583>.
- [61] Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Netw Open* 2020;3:e208857–e208857. <https://doi.org/10.1001/jamanetworkopen.2020.8857>.
- [62] Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, et al. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. *Circ Arrhythm Electrophysiol* 2020. <https://doi.org/10.1161/CIRCEP.120.008662>.
- [63] Huang M, Li M, Xiao F, Pang P, Liang J, Tang T, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. *Natl Sci Rev* n.d. <https://doi.org/10.1093/nsr/nwaa113>.
- [64] Khamis F, Al-Zakwani I, Al Naamani H, Al Lawati S, Pandak N, Omar MB, et al. Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: An experience from Oman. *Journal of Infection and Public Health* 2020. <https://doi.org/10.1016/j.jiph.2020.06.002>.
- [65] Fontana F, Alfano G, Mori G, Amurri A, Tei L, Ballestri M, et al. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine. *American Journal of Transplantation* 2020;20:1902–6. <https://doi.org/10.1111/ajt.15935>.
- [66] Mallat J, Hamed F, Balkis M, Mohamed MA, Mooty M, Malik A, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. *MedRxiv* 2020:2020.04.27.20082180. <https://doi.org/10.1101/2020.04.27.20082180>.
- [67] Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. *Ann Intern Med* 2020. <https://doi.org/10.7326/M20-2496>.
- [68] Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. *Rheumatology*; 2020. <https://doi.org/10.1101/2020.04.08.20054551>.
- [69] Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). *Journal of Clinical Epidemiology* 2011;64:407–15. <https://doi.org/10.1016/j.jclinepi.2010.07.017>.
- [70] Bessière F, Rocchia H, Delinière A, Charrière R, Chevalier P, Argaud L, et al. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. *JAMA Cardiol* 2020. <https://doi.org/10.1001/jamacardio.2020.1787>.
- [71] Bessière F, Rocchia H, Delinière A, Charrière R, Chevalier P, Argaud L, et al. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. *JAMA Cardiol* 2020. <https://doi.org/10.1001/jamacardio.2020.1787>.
- [72] Chorin E, Wadhvani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, et al. QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin. *Heart Rhythm* 2020. <https://doi.org/10.1016/j.hrthm.2020.05.014>.
- [73] Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant

- Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020. <https://doi.org/10.1001/jamacardio.2020.1834>.
- [74] Nguyen LS, Dolladille C, Drici M-D, Fenioux C, Alexandre J, Mira J-P, et al. Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database. *Circulation* 2020;142:303–5. <https://doi.org/10.1161/CIRCULATIONAHA.120.048238>.
- [75] Commissioner O of the. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. FDA 2020. <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and> (accessed June 15, 2020).
- [76] Agence Nationale de Sécurité du médicament et des produits de santé (ANSM). COVID-19 : l'ANSM souhaite suspendre par précaution les essais cliniques évaluant l'hydroxychloroquine dans la prise en charge des patients - Point d'Information - ANSM : Agence nationale de sécurité du médicament et des produits de santé n.d. <https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/COVID-19-l-ANSM-souhaite-suspendre-par-precaution-les-essais-cliniques-evaluant-l-hydroxychloroquine-dans-la-prise-en-charge-des-patients-Point-d-Information> (accessed June 15, 2020).
- [77] DIMITROVA EK. COVID-19: reminder of risk serious side effects with chloroquine and hydroxychloroquine. European Medicines Agency 2020. <https://www.ema.europa.eu/en/news/covid-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquine> (accessed June 15, 2020).
- [78] Rath S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. *The Lancet Infectious Diseases* 2020;0. [https://doi.org/10.1016/S1473-3099\(20\)30313-3](https://doi.org/10.1016/S1473-3099(20)30313-3).
- [79] Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, et al. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. *J Clin Epidemiol* 2020. <https://doi.org/10.1016/j.jclinepi.2020.04.016>.
- [80] NIH halts clinical trial of hydroxychloroquine. National Institutes of Health (NIH) 2020. <https://www.nih.gov/news-events/news-releases/nih-halts-clinical-trial-hydroxychloroquine> (accessed June 22, 2020).
- [81] WHO (World Health Organization). “Solidarity” clinical trial for COVID-19 treatments n.d. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments> (accessed June 8, 2020).
- [82] McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? *The Lancet* 2000;356:1228–31. [https://doi.org/10.1016/S0140-6736\(00\)02786-0](https://doi.org/10.1016/S0140-6736(00)02786-0).
- [83] Hopewell S, McDonald S, Clarke MJ, Egger M. Grey literature in meta-analyses of randomized trials of health care interventions. *Cochrane Database of Systematic Reviews* 2007. <https://doi.org/10.1002/14651858.MR000010.pub3>.
- [84] US NIH. Hydroxychloroquine plus Azithromycin | Coronavirus Disease COVID-19. COVID-19 Treatment Guidelines 2020. <https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/hydroxychloroquine-plus-azithromycin/> (accessed August 10, 2020).
- [85] INSERM. Discovery stopping inclusions in two treatment groups 2020. <https://presse.inserm.fr/en/discovery-stopping-inclusions-in-two-treatment-groups/40087/> (accessed August 10, 2020).

List of figures

Figure 1: Flow diagram of study selection process

Figure 2: Forest plot of the association between hydroxychloroquine alone and COVID-19 mortality*

Figure 3: Forest plot of the association between hydroxychloroquine with azithromycin and COVID-19 mortality*

Figure 1: Flow diagram of study selection process




Figure 2: Forest plot of the association between hydroxychloroquine alone and COVID-19 mortality*

*Excluding studies with critical risk of bias

RR=Risk Ratio 95%-CI= 95% Confidence Interval




Figure 3: Forest plot of the association between hydroxychloroquine with azithromycin and COVID-19 mortality*

*Excluding studies with critical risk of bias

RR=Risk Ratio 95%-CI= 95% Confidence Interval

